GlassScriptPhysician profile
Fabiola Feldhaus
NPI 1407149263
$3,615.03
in general payments reported to CMS, 2019-2025
43 companies · $245 in 2025
The $245 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $924 · 2020: $602 · 2021: $871 · 2022: $671 · 2023: $193 · 2024: $108 · 2025: $245.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $547.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $546.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $895.40 | 2019-2025 | Wegovy, Rybelsus, Ozempic |
| Abbvie INC. | $280.18 | 2021-2025 | |
| Lilly USA, LLC | $200.15 | 2019-2025 | Mounjaro, Zepbound |
| Astrazeneca Pharmaceuticals LP | $168.26 | 2019-2021 | |
| Amgen INC. | $166.83 | 2019-2022 | |
| Amarin Pharma, INC. | $160.03 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $127.71 | 2021-2024 | Jardiance |
| Takeda Pharmaceuticals U.S.A., INC. | $121.32 | 2019-2023 | Trintellix |
| Pfizer INC. | $109.45 | 2019-2022 | |
| Allergan, INC. | $107.57 | 2019-2020 | |
| Abbott Laboratories | $105.23 | 2024-2025 | Freestyle Libre 3 |
| Esperion Therapeutics, INC. | $101.06 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $91.48 | 2020-2022 | |
| Dexcom, INC. | $86.27 | 2021-2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $83.64 | 2019-2021 |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Fabiola Feldhaus listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.